Business Wire10.17.17
Insulet Corporation, a developer of tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), has broken ground on a new, state-of-the-art manufacturing facility on a 26-acre site in Acton, Mass.
The new facility represents a significant investment in Massachusetts, is expected to create hundreds of local jobs, and will provide additional manufacturing capabilities closer to Insulet’s large and growing U.S. customer base, according to the company. The new U.S. manufacturing operation is also expected to drive operating efficiencies and increase productivity. The company plans to begin production at this location in 2019.
“We are excited to see Insulet’s continued growth in Massachusetts, including the manufacturing jobs and innovations that will come from this new Acton facility,” Massachusetts Gov. Charlie Baker said at the groundbreaking ceremony. “Insulet has called the Commonwealth home for nearly 20 years, investing in our communities, providing jobs and developing technologies and products that better serve patients around the globe.”
“Investing in our manufacturing facility allows us to increase our capacity to better support our Omnipod customers, create local jobs and further strengthen our commitment to Massachusetts,” said Patrick Sullivan, chairman and CEO of Insulet Corporation. “We are experiencing significant growth across our business, and this facility will help us achieve our long-term objectives. I am grateful to Governor Baker and his staff, as well as the Acton community, for supporting all of our efforts. We are committed to providing world-class service to our Podders and improving the lives of those living with diabetes.”
Insulet Corporation seeks to expand the use of insulin pump therapy with its Omnipod Insulin Management System among people with insulin-dependent diabetes. The Omnipod System is a tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Mass.
The new facility represents a significant investment in Massachusetts, is expected to create hundreds of local jobs, and will provide additional manufacturing capabilities closer to Insulet’s large and growing U.S. customer base, according to the company. The new U.S. manufacturing operation is also expected to drive operating efficiencies and increase productivity. The company plans to begin production at this location in 2019.
“We are excited to see Insulet’s continued growth in Massachusetts, including the manufacturing jobs and innovations that will come from this new Acton facility,” Massachusetts Gov. Charlie Baker said at the groundbreaking ceremony. “Insulet has called the Commonwealth home for nearly 20 years, investing in our communities, providing jobs and developing technologies and products that better serve patients around the globe.”
“Investing in our manufacturing facility allows us to increase our capacity to better support our Omnipod customers, create local jobs and further strengthen our commitment to Massachusetts,” said Patrick Sullivan, chairman and CEO of Insulet Corporation. “We are experiencing significant growth across our business, and this facility will help us achieve our long-term objectives. I am grateful to Governor Baker and his staff, as well as the Acton community, for supporting all of our efforts. We are committed to providing world-class service to our Podders and improving the lives of those living with diabetes.”
Insulet Corporation seeks to expand the use of insulin pump therapy with its Omnipod Insulin Management System among people with insulin-dependent diabetes. The Omnipod System is a tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Mass.